Table 1.

Ultraviolet (UV)-B-induced apoptosis in the presence of inhibitors of cellular dynamic and motility

Target	Inhibitor	Action	Inhibitor (conc.)	Observations
F-actin	Jasplakinolide	Stabilizer of F-actin	50 nM	Cells disaggregate immediately into small exocytotic vesicles. Weak contraction of cell body. Late ACMVL contain H2BGFP
G-actin	Latrunculin A	Inhibitor of G-actin	5 μM	Intermediate exocytotic vesicles. Plastic nuclei, plane periphery with small motile branches. Late ACMVL contain H2BGFP
p160ROCK	(R)-(+)-trans-N-(4-Pyridyl)-4-(1-aminoethyl)-cyclohexanecarboxamide) (Y27632)	Inhibitor of Rho-associated protein kinase (p160ROCK)	5 μM	Some cells: strong contraction, extensive blebbing and chromatin condensation. Other cells cannot contract properly, sporadic late ACMVL contain H2BGFP
Myosin S1 ATPase	N-Benzyl-p-toluenesulphonamide (BTS)	Inhibitor of myosin S1-ATPase	125 μM	Cells bring their morphology into a round figure: strong contraction and condensation of chromatin. Late ACMVL contain H2BGFP
MLCK	1-(5-chloronaphthalene-1-sulphonyl)homopiperazine, HCl (ML-9)	Inhibitor of myosin light chain kinase (MLCK)	10 μM	No characteristic morphological changes during apoptosis. Strong condensation of chromatin and shrinkage of nuclei. No H2BGFP in late ACMVL
Tubulin (β-subunit)	Baccatin III N-benzyl-β-phenylisoserine Ester, Taxol® (Paclitaxel)	Stabilizer of microtubules	25 μM	No characteristic morphological changes during apoptosis. Faint condensation of chromatin, no/weak shrinkage of nuclei. No H2BGFP in late ACMVL

For each condition a total of approximately 50 cells was observed and analysed accurately in fluorescence microscopy. ACMV = apoptotic cell-derived membranous vesicles; H2B^GFP = histone 2-green fluorescent protein; ML-9 = 1-(5-chloronaphthalene-1-sulphonyl)-1H-hexahydro-1,4-diazepine. MLCK = myosin light chain kinase; ROCK = Rho-associated protein kinase.